{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:08:02Z","timestamp":1789380482411,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR) define a molecular subtype of colorectal cancer (CRC) and predict benefit from immune checkpoint inhibition. Clinically, MSI\/MMR assessment may yield discordant results across assays, anatomic sites, or time points. A challenging scenario occurs when tissue analysis identifies microsatellite-stable (MSS) or mismatch repair-proficient (pMMR) CRC, whereas circulating tumor DNA (ctDNA) analysis indicates MSI-H. This review evaluates evidence for MSI\/MMR heterogeneity and subclonality in CRC. We reviewed literature on spatial, temporal and subclonal MSI\/MMR heterogeneity across human cancers, focusing on CRC. Explanations for tissue\u2013plasma and tissue\u2013tissue discordance, including assay limitations, sampling bias, lesions misattribution, biological evolution, and treatment-related selection, were assessed. Although discordance more commonly reflects assay limitations, sampling bias, or profiling of different lesions, increasing evidence supports genuine biological heterogeneity. Distinct tumor regions may show retained MMR protein expression in one area and regional loss with MSI in another. Noncanonical MMR defects, epigenetic heterogeneity, post-treatment evolution, adaptive mutator-state, and immune selection may also generate dynamic or subclonal instability. Therapeutic relevance may depend not simply on MSI detection, but on whether the unstable clone is sufficiently dominant to generate broadly shared neoantigens across the disease burden. MSI\/MMR discordance requires careful interpretation and should not automatically be considered as true biological heterogeneity. Nevertheless, genuine subclonality occurs in CRC and other cancers and may affect responsiveness to immune checkpoint inhibition. Integrated tissue, plasma, spatial and longitudinal analyses may improve treatment decisions and biomarker development.<\/jats:p>","DOI":"10.3390\/cancers18182955","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:34:01Z","timestamp":1789378441000},"page":"2955","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microsatellite Instability and Mismatch Repair Subclonality in Human Cancers: Biologic Basis, Diagnostic Pitfalls, and Therapeutic Implications with a Focus on Colorectal Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Alena A.","family":"Hasenburg","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley G.","family":"Somer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Cancer Center and Research Institute, Germantown, TN 38138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Cancer Center and Research Institute, Germantown, TN 38138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Evrard, C., Tachon, G., Randrian, V., Karayan-Tapon, L., and Tougeron, D. (2019). Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers, 11.","DOI":"10.3390\/cancers11101567"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in Microsatellite-Instability\u2013High Metastatic Colorectal Cancer","volume":"391","author":"Elez","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial","volume":"405","author":"Elez","year":"2025","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cjp2.120","article-title":"Heterogenous loss of mismatch repair (MMR) protein expression: A challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation","volume":"5","author":"McCarthy","year":"2019","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.bjc.6600474","article-title":"Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas","volume":"87","author":"Chapusot","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_13","unstructured":"Ward, J.D., and Hiemenz, M. (2026, July 26). Navigating Discordant MMR\/MSI Test Results. Available online: https:\/\/www.cap.org\/article\/mismatches-in-mismatch-repair-navigating-discordant-mmr-msi-test-results\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cncr.35030","article-title":"Characterization of mismatch-repair\/microsatellite instability-discordant endometrial cancers","volume":"130","author":"Riedinger","year":"2024","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100120","DOI":"10.1016\/j.esmoop.2021.100120","article-title":"Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer","volume":"6","author":"Tachon","year":"2021","journal-title":"ESMO Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.5858\/arpa.2021-0632-CP","article-title":"Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer","volume":"146","author":"Bartley","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/PAS.0b013e31816401bb","article-title":"Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting","volume":"32","author":"Overbeek","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/PGP.0000000000000594","article-title":"Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report","volume":"39","author":"Chapel","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chowdhury, S., Hofree, M., Lin, K., Maru, D., Kopetz, S., and Shen, J.P. (2021). Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194923"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.modpat.2022.100012","article-title":"Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features","volume":"36","author":"Berrino","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105142","DOI":"10.1016\/j.ebiom.2024.105142","article-title":"Microsatellite instability in mismatch repair proficient colorectal cancer: Clinical features and underlying molecular mechanisms","volume":"103","author":"Xu","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41379-019-0414-6","article-title":"Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes","volume":"33","author":"Hechtman","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair\u2013Deficient\/Microsatellite Instability\u2013High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41588-024-01777-9","article-title":"Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer","volume":"56","author":"Kayhanian","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41416-023-02395-8","article-title":"Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers","volume":"129","author":"Kobayashi","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.6279","article-title":"Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy","volume":"263","author":"Geurts","year":"2024","journal-title":"J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2100383","DOI":"10.1200\/PO.21.00383","article-title":"Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy","volume":"6","author":"Nakamura","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tieng, F.Y.F., Abu, N., Lee, L.-H., and Ab Mutalib, N.-S. (2021). Microsatellite Instability in Colorectal Cancer Liquid Biopsy\u2014Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker. Diagnostics, 11.","DOI":"10.3390\/diagnostics11030544"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H\/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-026-10405-x","article-title":"Prospective evaluation of genomics-guided off-label treatment","volume":"653","author":"Verkerk","year":"2026","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000417","article-title":"B2M and JAK1\/2\u2013mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J. Immunother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2955\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:48:03Z","timestamp":1789379283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":35,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182955"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182955","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}